Site‐Specific Modification of Virus‐Like Particles for Exogenous Tumor Antigen Display and Minimizing Preexisting Immunity

Author:

Cheng Keman1,Ma Nana1,Liang Jie1,Ma Xiaotu1,Feng Qingqing1,Liu Guangna1,Xu Chen1,Tang Ming1,Zhang Lizhuo1,Gao Xiaoyu1,Xu Jiaqi1,Wang Chufan1,Zhu Fei1,Wang Xinwei1,Li Xiang2ORCID,Zhao Xiao134ORCID,Nie Guangjun13

Affiliation:

1. CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety CAS Center for Excellence in Nanoscience National Center for Nanoscience and Technology No. 11 Zhongguancun Beiyitiao Beijing 100190 P. R. China

2. School of Pharmacy Second Military Medical University Shanghai 200433 P. R. China

3. Center of Materials Science and Optoelectronics Engineering University of Chinese Academy of Sciences Beijing 100049 P. R. China

4. IGDB‐NCNST Joint Research Center Institute of Genetics and Developmental Biology Chinese Academy of Sciences Beijing 100101 P. R. China

Abstract

AbstractThe widespread preexisting immunity against virus‐like particles (VLPs) seriously limits the applications of VLPs as vaccine vectors. Enabling technology for exogenous antigen display should not only ensure the assembly ability of VLPs and site‐specific modification, but also consider the effect of preexisting immunity on the behavior of VLPs in vivo. Here, combining genetic code expansion technique and synthetic biology strategy, a site‐specific modification method for hepatitis B core (HBc) VLPs via incorporating azido‐phenylalanine into the desired positions is described. Through modification position screening, it is found that HBc VLPs incorporated with azido‐phenylalanine at the main immune region can effectively assemble and rapidly conjugate with the dibenzocycolctyne‐modified tumor‐associated antigens, mucin‐1 (MUC1). The site‐specific modification of HBc VLPs not only improves the immunogenicity of MUC1 antigens but also shields the immunogenicity of HBc VLPs themselves, thereby activating a strong and persistent anti‐MUC1 immune response even in the presence of preexisting anti‐HBc immunity, which results in the efficient tumor elimination in a lung metastatic mouse model. Together, these results demonstrate the site‐specific modification strategy enabled HBc VLPs behave as a potent antitumor vaccine and this strategy to manipulate immunogenicity of VLPs may be suitable for other VLP‐based vaccine vectors.

Funder

Natural Science Foundation of Beijing Municipality

Beijing Nova Program

National Natural Science Foundation of China

China Postdoctoral Science Foundation

Publisher

Wiley

Subject

Biomaterials,Biotechnology,General Materials Science,General Chemistry

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3